Zobrazeno 1 - 10
of 648
pro vyhledávání: ''
Autor:
Kazuki Furuhashi, Katsuhiro Yoshimura, Masato Karayama, Noriyuki Enomoto, Naoki Inui, Hironao Hozumi, Takafumi Suda, Yutaro Nakamura, Yuzo Suzuki, Yusuke Inoue, Tomoyuki Fujisawa
Publikováno v:
Journal of Immunotherapy. 45:125-131
The nutritional status has the potential to affect cancer immunity. We evaluated the relationship between the nutritional status and the efficacy of nivolumab in patients with non-small cell lung cancer (NSCLC). This study was a post hoc analysis of
Autor:
Hiroshi Uchi, Satoshi Fukushima, Yuki Yamamoto, Shigeto Matsushita, Hiroshi Kato, Yasuhiro Fujisawa, Ryo Amagai, Takeo Maekawa, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Koji Yoshino, Taku Fujimura
Publikováno v:
Melanoma Research. 31:575-578
Patients with resected stage IIIB, IIIC and IIID melanomas have a high risk of recurrence. Therefore, an appropriate protocol for stage III melanoma is needed. Since adjuvant dabrafenib plus trametinib (D+T) combined therapy and anti-PD1 antibody (Ab
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Publikováno v:
Anti-Cancer Drugs. 32:1127-1130
Avapritinib is a tyrosine kinase inhibitor currently being investigated on clinical trials for the treatment of unresectable or metastatic gastrointestinal stromal tumour (GIST). It has been recently approved by the Food and Drug Administration and t
Autor:
Gina Klee, Patrick Terheyden, Jonas K. Kurzhals, Victoria Hagelstein, Detlef Zillikens, Ewan A. Langan, Andreas Recke
Publikováno v:
Melanoma Research. 31:464-471
Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined w
Autor:
Cuizhen Liu, Xinping Ye, Yanfeng Jiang, Guangzhi Zhu, Jing Tang, Tao Peng, Jie Ma, Zhiming Zeng, Jie Zeng, Fuchao Ma, Jinfeng Qiu, Lihua Yang
Publikováno v:
Anti-Cancer Drugs. 32:1093-1098
This study was to explore the efficacy and safety of camrelizumab combined with apatinib in patients with advanced liver cancer. Moreover, the relationship between peripheral blood parameters and tumor response rate was also investigated. Patients wi
Autor:
Aline Charabaty, Zimu Gong, Pablo C. Okhuysen, Yuanzun Peng, Yinghong Wang, Jennifer L. McQuade, Hao Chi Zhang, Mehmet Altan, Hamzah Abu-Sbeih, Weijie Ma, Frederick B. Peng, Fangwen Zou, Anusha Shirwaikar Thomas
Publikováno v:
American Journal of Clinical Oncology. 44:402-408
Background and objective Immune-mediated diarrhea and colitis (IMDC) is a common adverse event in cancer patients receiving immune checkpoint inhibitors (ICIs). Gastrointestinal (GI) infections can co-occur with IMDC, and its impact on the course and
Autor:
Jose Mauricio Mota, Min Yuen Teo, Karissa Whiting, Samuel Funt, Chung-Han Lee, Han A Li, Gopa Iyer, Jonathan E. Rosenberg, Ashely M Regazzi, Dean F. Bajorin, Irina Ostrovnaya
Publikováno v:
J Immunother
Eosinophils influence antitumor immunity and may predict response to treatment with immune checkpoint inhibitors (ICIs). To examine the association between blood eosinophil counts and outcomes in patients with advanced or metastatic urothelial carcin
Autor:
Shannon L. Golden, Angela Tatiana Alistar, Christopher Y. Thomas, Rodwige J. Desnoyers, Alexandra Thomas, Scott Isom, Stefan C. Grant, Patricia E. Gallagher, Rhonda L. Bitting, E. Ann Tallant, Katherine Pleasant, Heidi D. Klepin, Mark C. Chappell, W. Jeffrey Petty, Janet A. Tooze
Publikováno v:
Am J Clin Oncol
Objective Preclinical studies with muscadine grape extract (MGE) show antitumor activity and decreased systemic inflammation. This phase I study (NCT02583269) assessed safety and tolerability of a proprietary MGE preparation in patients with advanced
Publikováno v:
Melanoma Research. 31:242-248
Twenty to sixty percent of patients receiving immune checkpoint inhibitors (ICIs) experience high-grade immune-related adverse events (irAEs) which may prevent the continuation of treatment. Limited clinical evidence is available to guide treatment f